GSK
3 years ago ⋅ English ⋅ 7 min read
Newsroom
GSK to present updates on its industry-leading infectious disease portfolio at IDWeek 2022

For media and investors onlyFirst presentation of RSV Older Adult vaccine candidate’s pivotal phase III efficacy and safety dataNew data showing Shingrix efficacy and safety over... Read More
GSK
3 years ago ⋅ English ⋅ 3 min read
Newsroom
US FDA approves BOOSTRIX for immunisation during pregnancy for the prevention of whooping cough in newborn infants

For media and investors only- BOOSTRIX is the first vaccine indicated in the US to help protect infants younger than two months from pertussis (whooping cough)GSK plc (LSE/NYSE: GSK) to... Read More
GSK
3 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK announces positive headline results from PERLA, the phase II trial of Jemperli (dostarlimab) plus chemotherapy in patients with metastatic non-squamous non-small cell lung cancer

For media and investors onlyPERLA is the largest global head-to-head trial of PD-1 inhibitors in this populationCOSTAR, the phase II/III trial combining dostarlimab with cobolimab, a TI... Read More
GSK
3 years ago ⋅ English ⋅ 6 min read
Newsroom
Iain Mackay, Chief Financial Officer, to retire from GSK, Julie Brown appointed as successor

For media and investors onlyGSK plc (LSE/NYSE: GSK) today announced that Iain Mackay, Chief Financial Officer (CFO), has decided to retire from GSK. The Board has agreed that he will st... Read More
GSK
3 years ago ⋅ English ⋅ 5 min read
Newsroom
Oncologic Drugs Advisory Committee to review Zejula overall survival data from the NOVA phase III trial in recurrent ovarian cancer

For media and investors onlyGSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) will convene a meeting of the Oncologic Drugs Advisory Committee (ODAC... Read More
GSK
3 years ago ⋅ English ⋅ 6 min read
Newsroom
GSK and Spero Therapeutics announce exclusive licence agreement for tebipenem HBr, a late-stage antibiotic that may treat complicated urinary tract infections

For media and investors onlyThe exclusive licence allows GSK to commercialise tebipenem HBr in all regions except for Japan and certain other Asian countriesSpero Therapeutics receives... Read More